What is a stock summary page? Click here for an overview.
Business Description
Puma Biotechnology Inc
NAICS : 325412
SIC : 2834
ISIN : US74587V1070
Compare
Compare
Traded in other countries / regions
PBYI.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2012-03-21Description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.36 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.8 | |||||
| Debt-to-EBITDA | 1.54 | |||||
| Interest Coverage | 2.49 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -5.98 | |||||
| Beneish M-Score | -2.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9 | |||||
| 3-Year EPS without NRI Growth Rate | 113.6 | |||||
| 3-Year FCF Growth Rate | 15.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -21.07 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -2.18 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.27 | |||||
| 9-Day RSI | 37.3 | |||||
| 14-Day RSI | 40.77 | |||||
| 3-1 Month Momentum % | -1.13 | |||||
| 6-1 Month Momentum % | 32.45 | |||||
| 12-1 Month Momentum % | -39.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.54 | |||||
| Quick Ratio | 1.45 | |||||
| Cash Ratio | 1.05 | |||||
| Days Inventory | 39.25 | |||||
| Days Sales Outstanding | 59.29 | |||||
| Days Payable | 48.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6 | |||||
| Shareholder Yield % | 13.99 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.06 | |||||
| Operating Margin % | 13.44 | |||||
| Net Margin % | 13.14 | |||||
| FCF Margin % | 16.89 | |||||
| ROE % | 47.89 | |||||
| ROA % | 13.97 | |||||
| ROIC % | 30.5 | |||||
| 3-Year ROIIC % | 123.83 | |||||
| ROC (Joel Greenblatt) % | 503.86 | |||||
| ROCE % | 31.76 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 4.58 | |||||
| Forward PE Ratio | 6.98 | |||||
| PE Ratio without NRI | 3.58 | |||||
| Price-to-Owner-Earnings | 7.45 | |||||
| PS Ratio | 0.57 | |||||
| PB Ratio | 1.49 | |||||
| Price-to-Tangible-Book | 3.33 | |||||
| Price-to-Free-Cash-Flow | 3.38 | |||||
| Price-to-Operating-Cash-Flow | 3.38 | |||||
| EV-to-EBIT | 3.23 | |||||
| EV-to-EBITDA | 2.45 | |||||
| EV-to-Revenue | 0.51 | |||||
| EV-to-Forward-Revenue | 0.54 | |||||
| EV-to-FCF | 3.01 | |||||
| Price-to-GF-Value | 0.95 | |||||
| Price-to-Projected-FCF | 0.66 | |||||
| Price-to-Graham-Number | 0.73 | |||||
| Price-to-Net-Current-Asset-Value | 5.16 | |||||
| Earnings Yield (Greenblatt) % | 30.96 | |||||
| FCF Yield % | 28.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PBYI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Puma Biotechnology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 230.468 | ||
| EPS (TTM) ($) | 0.61 | ||
| Beta | 1.42 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.72 | ||
| Volatility % | 59.21 | ||
| 14-Day RSI | 40.77 | ||
| 14-Day ATR ($) | 0.201592 | ||
| 20-Day SMA ($) | 3.155 | ||
| 12-1 Month Momentum % | -39.79 | ||
| 52-Week Range ($) | 2.225 - 5.8 | ||
| Shares Outstanding (Mil) | 49.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Puma Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Puma Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Puma Biotechnology Inc Frequently Asked Questions
What is Puma Biotechnology Inc(PBYI)'s stock price today?
The current price of PBYI is $2.80. The 52 week high of PBYI is $5.80 and 52 week low is $2.23.
When is next earnings date of Puma Biotechnology Inc(PBYI)?
The next earnings date of Puma Biotechnology Inc(PBYI) is 2025-05-02 Est..
Does Puma Biotechnology Inc(PBYI) pay dividends? If so, how much?
Puma Biotechnology Inc(PBYI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers